Clinical Trials Logo
  1. Home
  2. Graves Ophthalmopathy
  3. NCT03122847

Glucocorticoids and Bone in Graves' Ophthalmopathy

Graves Ophthalmopathy Clinical Trial

Official title:
The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy

Clinical Trial Summary

Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.

Clinical Trial Description

Systemic glucocorticoid increases bone resorption and decreases bone formation and thereby decreases bone mineral density and increases fracture risk. This effect is evident with a daily dose of 5 mg for three months or an accumulated dose of 450mg. There is, however, less evidence that intermittent use of glucocorticoids is harmful to bone. Graves orbitopathy is treated with a weekly infusion of the glucocorticoid methylprednisolone and the accumulated dose over a 12-week course sums up to 4,500mg. The investigators therefore want to investigate if that treatment regimen affects bone turnover, bone mineral density, or bone structure in 30 patients with Graves' orbitopathy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03122847
Study type Observational
Source Aarhus University Hospital
Contact
Status Active, not recruiting
Phase
Start date June 7, 2017
Completion date July 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05532072 - Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. Early Phase 1
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Recruiting NCT03708627 - Bimatoprost as a Treatment for Graves' Orbitopathy Early Phase 1
Not yet recruiting NCT06413043 - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy N/A
Withdrawn NCT01379196 - Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy Phase 1/Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Recruiting NCT05126147 - Hydroxychloroquine in Mild Graves' Orbitopathy Phase 4
Recruiting NCT01999790 - Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy N/A
Recruiting NCT03066076 - Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Phase 3
Terminated NCT01893450 - Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment N/A
Completed NCT00348413 - Thyroid Treatment Trial N/A
Completed NCT03498417 - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Not yet recruiting NCT04598815 - Sirolimus for Graves' Orbitopathy (GO) Phase 2
Terminated NCT01114503 - A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Phase 2
Completed NCT05775185 - Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
Completed NCT05793359 - Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
Recruiting NCT02203682 - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy Phase 2